Credifinance Capital

Cardiff Oncology is a clinical-stage biotechnology company focused on developing onvansertib, a first-in-class, oral, highly selective Polo-like Kinase 1 (PLK1) inhibitor. The company's lead program evaluates onvansertib in combination with standard-of-care therapies for the treatment of RAS-mutated metastatic colorectal cancer (mCRC). Beyond mCRC, Cardiff Oncology is conducting clinical trials in other difficult-to-treat cancers, including metastatic pancreatic ductal adenocarcinoma and small cell lung cancer. The company's therapeutic strategy aims to overcome resistance to existing treatments by targeting the PLK1 pathway, which is essential for cancer cell mitosis. Cardiff Oncology was formerly known as Trovagene and Credifinance Capital Corp and is headquartered in San Diego, California.